M3 leukemia, also known as acute promyelocytic leukemia, has a 10-year survival rate of more than 90% after cure, which means that long-term survival without relapse can be achieved. This is because M3 leukemia is mainly due to the fact that the causative gene is clearly PML-RARĪ±, and there is a specific target drug for this mutation, which is all-trans retinoic acid plus arsenic, on the basis of which a small dose of chemotherapy can be used to maintain M3 leukemia in long-term remission without relapse. Therefore, once M3 leukemia is cured and in remission, it can be treated without bone marrow suppression or stem cell transplantation, and is a hematologic malignancy with a very good prognosis.